收费全文 | 577篇 |
免费 | 45篇 |
耳鼻咽喉 | 1篇 |
儿科学 | 5篇 |
妇产科学 | 5篇 |
基础医学 | 61篇 |
口腔科学 | 3篇 |
临床医学 | 40篇 |
内科学 | 261篇 |
皮肤病学 | 14篇 |
神经病学 | 29篇 |
特种医学 | 15篇 |
外科学 | 46篇 |
综合类 | 9篇 |
预防医学 | 60篇 |
药学 | 53篇 |
中国医学 | 1篇 |
肿瘤学 | 19篇 |
2022年 | 3篇 |
2021年 | 16篇 |
2020年 | 7篇 |
2019年 | 16篇 |
2018年 | 16篇 |
2017年 | 8篇 |
2016年 | 5篇 |
2014年 | 7篇 |
2013年 | 6篇 |
2012年 | 24篇 |
2011年 | 28篇 |
2010年 | 19篇 |
2009年 | 14篇 |
2008年 | 28篇 |
2007年 | 23篇 |
2006年 | 26篇 |
2005年 | 30篇 |
2004年 | 24篇 |
2003年 | 25篇 |
2002年 | 29篇 |
2001年 | 31篇 |
2000年 | 33篇 |
1999年 | 17篇 |
1998年 | 12篇 |
1996年 | 5篇 |
1995年 | 8篇 |
1994年 | 5篇 |
1993年 | 5篇 |
1992年 | 9篇 |
1991年 | 10篇 |
1990年 | 15篇 |
1989年 | 9篇 |
1988年 | 6篇 |
1987年 | 3篇 |
1986年 | 7篇 |
1985年 | 7篇 |
1984年 | 4篇 |
1983年 | 6篇 |
1981年 | 3篇 |
1980年 | 3篇 |
1979年 | 6篇 |
1978年 | 12篇 |
1977年 | 4篇 |
1976年 | 8篇 |
1974年 | 3篇 |
1973年 | 8篇 |
1972年 | 5篇 |
1971年 | 5篇 |
1970年 | 4篇 |
1968年 | 2篇 |
JAMA. 2000;283:2417-2426.
Objective Assays for drug resistance testing in human immunodeficiency virus type 1 (HIV-1) infection are now available and clinical studies suggest that viral drug resistance is correlated with poor virologic response to new therapy. The International AIDS SocietyUSA sought to update prior recommendations to provide guidance for clinicians regarding indications for HIV-1 resistance testing. Participants An International AIDS SocietyUSA 13-member physician panel with expertise in basic science, clinical research, and patient care involving HIV resistance to antiretroviral drugs was reconvened to provide recommendations for the clinical use of drug resistance testing. Evidence and Consensus Process The full panel met regularly between January and October 1999. Resistance and resistance testing data appearing in the last decade through April 2000 and presentations at national and international research conferences were reviewed. Recommendations and considerations were developed by 100% group consensus, acknowledging that definitive data to support final recommendations are not yet available. Conclusions Emerging data indicate that despite limitations, resistance testing should be incorporated into patient management in some settings. Resistance testing is recommended to help guide the choice of new regimens after treatment failure and for guiding therapy for pregnant women. It should be considered in treatment-naive patients with established infection, but cannot be firmly recommended in this setting. Testing also should be considered prior to initiating therapy in patients with acute HIV infection, although therapy should not be delayed pending the results. Expert interpretation is recommended given the complexity of results and assay limitations.
Methods: A total of 1956 patients who met criteria for severe IBS-D were randomized to treatment with alosetron 1?mg twice daily (BID) or only TP for up to 24 weeks. Work productivity and resource use were evaluated by standard questionnaires, HRQOL by the IBSQOL instrument and IBS symptoms by the Global Improvement Scale (GIS).
Results: Compared to only TP, alosetron-treated patients reported: (1) fewer clinic/office visits for any health problem (p?=?.0181) or for IBS-D (p?=?.0004); (2) reduced use of over-the-counter medications for IBS-D (p < .0001); (3) fewer days of lost work productivity (p < .0001); (4) decreased restriction of social and outdoor activities (p < .0001); and (5) greater global improvement in IBS-D symptoms (p < .0001). Alosetron treatment improved HRQOL scores for all domains (p < .0001). Incidence of adverse events during alosetron use was not remarkable and was similar to that previously reported.
Conclusions: Alosetron 1?mg BID significantly reduced health care utilization and lost productivity, and significantly improved global IBS symptoms, HRQOL, and participation in outdoor and social activities compared with treatment response to TP. 相似文献